Tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a profile of its use

AbstractThe CD123-directed cytotoxin tagraxofusp (ELZONRIS®) is the first treatment approved in the EU for first-line treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults. BPDCN is a rare disease that affects mainly older patients and is usually treated with acute leukaemia-type multi-drug chemotherapy regimens followed, if possible, by stem cell transplantation (SCT). In the largest prospective trial conducted in BPDCN to date, treatment with tagraxofusp led to high rates of early and durable response in patients with previously untreated BPDCN, and enabled bridging to SCT in half of those who responded. The tolerability profile of tagraxofusp is well characterised, with most adverse events occurring during the first cycle of treatment, and many older patients who did not undergo transplantation were able to tolerate long term treatment, leading to prolonged responses. Tagraxofusp thus represents an important advance in the treatment of BPDCN, particularly for older patients who are unable to tolerate the multidrug chemotherapy regimens that until now have been the mainstay of treatment.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research